JC

James Calloway

Financial Reporter

James Calloway is a financial reporter at StockTi covering corporate earnings, regulatory policy, and market-moving events. A former business journalist with Reuters, James has covered financial markets for over eight years across New York and Washington. He specializes in breaking down earnings reports, SEC filings, and policy decisions that affect publicly traded companies and investor portfolios.

Earnings, Regulation 903 articles

Articles by James Calloway

Ford Issues Massive Recall for 1 Million Vehicles, Stock Dips
Regulation

Ford Issues Massive Recall for 1 Million Vehicles, Stock Dips

Ford Motor Company is initiating a recall covering approximately 1.02 million vehicles in the United States due to windshield wiper motor and rear suspension issues. The automaker's shares declined about 1% following the announcement.

F
Petrobras Stock Rises on Oil Price Rally, Dividend Outlook in Focus
Earnings

Petrobras Stock Rises on Oil Price Rally, Dividend Outlook in Focus

Petrobras shares climbed 4.3% Monday as surging crude prices renewed discussions about additional shareholder returns. The Brazilian oil giant reported a Q4 net profit of 15.6 billion reais, though executives indicated extra dividends are unlikely this year.

USO XLE
Costco Holds Cash, Focuses on Digital Growth After Strong Quarter
Earnings

Costco Holds Cash, Focuses on Digital Growth After Strong Quarter

Costco posted quarterly sales of $68.24 billion and net income of $2.04 billion, exceeding forecasts. The company holds $17.38 billion in cash but has no immediate plans for a special dividend, focusing instead on warehouse expansion and digital investments.

COST WMT
Red Cat Shares Retreat After Pentagon Drone Shortlist, Q4 Revenue Surge Awaited
Earnings

Red Cat Shares Retreat After Pentagon Drone Shortlist, Q4 Revenue Surge Awaited

Red Cat Holdings shares declined approximately 4% Monday after its drone unit was named a finalist for Pentagon contracts, tempering a recent rally. The company anticipates reporting a massive year-over-year revenue increase for its fourth quarter on March 18.

AVAV KTOS
Atara Biotherapeutics Surges on FDA Leadership Shift, EBVALLO Review in Focus
Regulation

Atara Biotherapeutics Surges on FDA Leadership Shift, EBVALLO Review in Focus

Atara Biotherapeutics shares surged 18% Monday following news of an upcoming FDA leadership change, reviving investor hope for a reconsideration of its rejected EBVALLO therapy for a rare blood cancer.

ATRA
Capricor Shares Gain Ahead of Key Duchenne Data and Financial Update
Earnings

Capricor Shares Gain Ahead of Key Duchenne Data and Financial Update

Capricor Therapeutics shares advanced 7.6% as the company prepares to release quarterly results and full Phase 3 data for its Duchenne muscular dystrophy drug deramiocel on March 12.

CAPR
Unusual Machines Shares Surge on Preliminary 2025 Revenue Doubling
Earnings

Unusual Machines Shares Surge on Preliminary 2025 Revenue Doubling

Unusual Machines shares climbed 7% Monday following preliminary results showing 2025 revenue more than doubled to $11.2 million and cash reserves topped $103 million. The drone components maker also reported a widened quarterly operating loss.

UMAC
W&T Offshore Posts Wider 2025 Loss Amid Revenue Drop, Sees Regulatory Relief
Earnings

W&T Offshore Posts Wider 2025 Loss Amid Revenue Drop, Sees Regulatory Relief

W&T Offshore disclosed a deeper net loss for 2025, with revenue declining to $501.5 million. The company highlighted reduced net debt and potential regulatory relief from proposed offshore financial assurance rules.

WTI TALO MUR USO XLE
Reviva Pharma Enacts Reverse Split to Fend Off Nasdaq Delisting
Regulation

Reviva Pharma Enacts Reverse Split to Fend Off Nasdaq Delisting

Reviva Pharmaceuticals Holdings has implemented a 1-for-20 reverse stock split to boost its share price and avoid a Nasdaq delisting, with a critical compliance deadline of March 27. The company also faces financing challenges for an additional Phase 3 trial of its schizophrenia drug candidate, brilaroxazine.

RVPH BMY VNDA XLV
uniQure Shares Soar on FDA Leadership Shift Amid Gene Therapy Dispute
Regulation

uniQure Shares Soar on FDA Leadership Shift Amid Gene Therapy Dispute

uniQure shares jumped 34% in premarket trading following news that FDA biologics chief Vinay Prasad will depart in April. The move comes amid a regulatory standoff over the company's Huntington's disease gene therapy.

QURE
3D Systems Tops Q4 Forecasts, but Bleak Q1 Outlook Raises Doubts
Earnings

3D Systems Tops Q4 Forecasts, but Bleak Q1 Outlook Raises Doubts

3D Systems reported Q4 revenue of $106.3M, exceeding its forecast, though full-year sales fell 12%. The company anticipates a revenue decline and continued losses for the current quarter.

DDD
Micron Shares Retreat Ahead of Key Index Inclusion and Earnings Report
Earnings

Micron Shares Retreat Ahead of Key Index Inclusion and Earnings Report

Micron Technology shares declined roughly 6.7% before Monday's opening bell, pressured by broader market weakness and anticipation surrounding upcoming earnings and index rebalancing.

MU AIG MET TGT LRCX AMAT